Drug-resistant TB poses a health emergency in India
Political resolve is required to protect people through early detection, safer treatment, holistic support, and committed follow-up
360° Perspective Analysis
Deep-dive into Geography, Polity, Economy, History, Environment & Social dimensions — AI-powered, on-demand
Context
An op-ed highlights a critical public health crisis: despite overall progress in combating Tuberculosis (TB), Drug-Resistant TB (DR-TB) remains a neglected emergency in India. The nation accounts for about a quarter of the world's DR-TB burden, with significant challenges in diagnosis, treatment access, and patient support systems. The article argues that this threatens to reverse India's gains against TB and requires urgent political and financial commitment.
UPSC Perspectives
Governance & Institutional Challenges
The DR-TB crisis exemplifies significant governance gaps in India's public health infrastructure. Despite the ambitious goals of the (NTEP) to end TB by 2025, the article points to uneven preparedness and implementation failures. For instance, while molecular diagnostic tools like and TrueNAT are part of the strategy, their inconsistent uptake, especially in rural areas, leads to diagnostic delays. This results in patients being put on incorrect first-line regimens, which fuels further resistance. The article criticizes the fragmented healthcare system, citing poor coordination between public and private sectors, stock-outs of essential second-line drugs, and weak data monitoring despite platforms like the . For UPSC, this connects to the theme of 'last-mile delivery' and 'state capacity', raising questions on the ability of our health systems to execute complex national programs and regulate a fragmented private sector. A potential Mains question could be: "Analyze the institutional and governance challenges hindering the success of the National Tuberculosis Elimination Programme, particularly in the context of rising Drug-Resistant TB. Suggest reforms for a more effective, patient-centric approach."
Social Justice & Equity
The article powerfully frames DR-TB as an issue of social justice, highlighting how it disproportionately affects the most vulnerable. This aligns with the UPSC concept of social determinants of health, where factors like poverty, malnutrition, and housing conditions directly impact health outcomes. DR-TB thrives in overcrowded homes and among those with precarious livelihoods, creating a vicious cycle of disease and poverty. The harsh treatment regimens cause severe side effects like hearing loss, leading to job loss and social stigma, which isolates patients and hampers treatment adherence. The catastrophic health expenditure, especially for those forced into the private sector, deepens intergenerational poverty. While the government has initiatives like the for nutritional support and the to encourage community support, the article implies their reach and effectiveness are insufficient to counter these deep-seated inequities. This links directly to the fundamental Right to Life and Health under of the Constitution. UPSC aspirants should analyze how public health crises like DR-TB are not merely biomedical problems but are rooted in social and economic structures.
Economic Impact & S&T Solutions
From an economic perspective, uncontrolled DR-TB poses a significant threat to India's human capital and economic stability. The disease primarily affects the working-age population (15-45 years), leading to a direct loss of workforce productivity due to prolonged illness and disability. The high cost of treatment, especially the multi-year, toxic regimens, leads to massive out-of-pocket expenditure (OOPE) for families, pushing them into debt. This economic burden at both micro and macro levels undermines national development goals. On the Science & Technology front, the article points to a path forward. While diagnostic challenges persist, the scaling of molecular tests like CBNAAT and TrueNAT is a positive step. More importantly, the introduction of newer, shorter, and safer all-oral regimens like BPaLM (Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin) offers a breakthrough. The successful rollout of the BPaLM regimen across India is crucial for improving cure rates, reducing toxicity, and making treatment more manageable for patients. The challenge for the government is to ensure the rapid and equitable scale-up of these new technologies and treatments to all who need them.